("EKF" or the "Company")
Share Buyback
Aggregated information
|
Date of purchase |
|
|
Number of Ordinary Shares purchased |
709,193 |
|
Highest price paid per Ordinary Share |
28p |
|
Lowest price paid per Ordinary Share |
28p |
|
Volume weighted average price paid |
28p |
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic
|
Number of Ordinary Shares purchased |
Transaction price (GBp) |
Time of transaction |
Trading venue |
|
500,000 |
28p |
11:19:37 |
AIMX |
|
209,193 |
28p |
15:51:08 |
AIMX |
Total voting rights
Following the purchase, the Company's total issued share capital will consist of 449,093,790 Ordinary Shares, of which 709,193 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 448,384,597. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
PDMR dealing
As part of the buyback and within the above aggregate purchase, EKF acquired 209,193 Ordinary Shares in total at a price of
Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company,
Additional disclosures relating to this PDMR dealing are detailed below.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
The person responsible for arranging the release of this Announcement
on behalf of the Company is
|
|
|||
|
|
via Walbrook PR |
||
|
|
|
||
|
|
Tel: +44 (0)20 7496 3000 |
||
|
|
|
||
|
|
|
||
|
|
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About
EKF is an AIM-listed global diagnostics business focussed on:
|
● |
Point-of-Care analysers in the key areas of Hematology and Diabetes |
|
● |
Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
|
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Non-Executive Director |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
|
|
|||
|
b)
|
LEI
|
213800DXTF3EAUK1AR05
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of |
|||
|
|
|
||||
|
Identification code |
GB0031509804
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Disposal of Ordinary Shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
28p |
209,193 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
n/a |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
|
|||
|
f)
|
Place of the transaction
|
|
|||
|
|
|
|
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the